DRUG RESISTANCE UPDATES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2025-08-27 ms3000001124115376 来自江西省

偏重的研究方向：肿瘤耐药;耐药
经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊

22 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2024-03-05 1851f102e3m 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：耐药
经验分享：以前是review杂志所以IF很高（>20）但知名度一般

2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望

有合适的文章不妨投一篇试试水

135 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2023-05-08 ms7000000365645384 来自北京

哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态...

139 7 举报

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2024-01-11 ms2000000680553522 来自江苏省

投稿命中率:25.0
偏重的研究方向：微生物耐药
经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？

136 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2024-06-29 ms3000000310778731 来自安徽省

偏重的研究方向：肿瘤耐药;耐药
经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受

135 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2025-02-17 科研X 来自江苏省

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：耐药抵抗
经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。

59 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2024-08-03 shuaiydemo 来自北京

偏重的研究方向：肿瘤耐药
经验分享：太太太太太太太慢了……

102 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2023-08-11 ms7000000365645384 来自北京

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：耐药
经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难

137 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2023-02-23 科研小帮来自广西

药物耐药性相关方向

151 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2278968, encodeId=094f22e896863, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：有谁投过这个杂志嘛，我投了当天就with editor，一般多久给一审决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a99775131, createdName=ms3000001124115376, createdTime=Wed Aug 27 21:02:22 CST 2025, time=2025-08-27, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2212279, encodeId=aade22122e9d8, content=偏重的研究方向：肿瘤耐药;耐药 经验分享：23年8月投稿，编辑17天，外审2个半月，大修6个月，二审14天，24年6月份接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25565484760, createdName=ms3000000310778731, createdTime=Sat Jun 29 07:52:31 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2252313, encodeId=6d552252313d8, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药抵抗 经验分享：药学耐药领域的顶刊了，近几年文章数量增加，因子跌到15.8，因子应该能回到原来20+。编辑要求及其严苛，不仅仅在创新性，文章实验设计细节，作图都提出了修改意见。三个审稿人提了一堆问题，问题上看均是小同行。建议研究方向一定对口，不对口做的再好也可能秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c42140786, createdName=科研X, createdTime=Mon Feb 17 10:32:28 CST 2025, time=2025-02-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218264, encodeId=d07822182643b, content=偏重的研究方向：肿瘤耐药 经验分享：太太太太太太太慢了……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Sat Aug 03 11:00:29 CST 2024, time=2024-08-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=)]

2022-08-07 病毒猎手

审稿速度:2.0 | 投稿命中率:25.0
经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates

170 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务